Skip to main content
. 2011 Dec 7;95(2):297–308. doi: 10.3945/ajcn.111.024927

FIGURE 5.

FIGURE 5.

Annualized incidence rate for progression to T2D. Data represent subjects without T2D at baseline. Standardized lifestyle intervention was used across all treatment groups. *P = 0.1514 compared with placebo; P = 0.0078 compared with placebo. PHEN/TPM CR 7.5/46, 7.5 mg phentermine/46 mg controlled-release topiramate; PHEN/TPM CR 15/92, 15 mg phentermine/92 mg controlled-release topiramate; T2D, type 2 diabetes.